Additional information
NA
1148113-53-4
ACI-011611
C23H21F7N4O3
534.43
Ambient
2-8°C
Anticancer
Pharmaceutical Impurity Standards
5-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one
(3-[[(2R,3R)-2-[(R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholino]methyl]-1H-1,2,4-triazol-5(4H)-one))
Aprepitant Related Compound A; Aprepitant EP Impurity E;(R,R,R)-Aprepitant





![TOFACITINIB DIMER (25 mg) (1,3-Bis{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-1-piperidinyl}-1,3-propanedione)](https://analyticachemie.in/wp-content/uploads/uspimage-1.jpg)